StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Audentes Therapeutics (BOLD) PT Raised to $44 at BMO Capital on 'AT123 Phase I & II Data... Significantly De-Risk the Program'
January 4, 2018 1:04 PM
BMO Capital raised its price target on Audentes Therapeutics (NASDAQ: BOLD) to $44.00 (from $35.00) while maintaining a Outperform ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Audentes Therapeutics (BOLD) PT Raised to $46 at Leerink Partners
January 5, 2018 7:45 AM
Audentes (BOLD) Reports Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With XLMTM
January 4, 2018 7:06 AM